#### Edgar Filing: LIGAND PHARMACEUTICALS INC - Form 4

#### LIGAND PHARMACEUTICALS INC

Form 4

February 14, 2014

# FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB 3235-0287 Number:

Check this box if no longer subject to Section 16.

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

January 31, Expires: 2005

0.5

**OMB APPROVAL** 

response...

Estimated average burden hours per

Form 4 or Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * FOEHR MATTHEW W			2. Issuer Name and Ticker or Trading Symbol LIGAND PHARMACEUTICALS INC [LGND]	5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)		
(Last) 11119 NORTH ROAD, SUITH		(Middle) PINES	3. Date of Earliest Transaction (Month/Day/Year) 02/12/2014	Director 10% Owner Officer (give title Other (specify below) EVP and COO		
LA JOLLA, C	(Street) A 92037		4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person		

(City)	(State)	(Zip) Tabl	e I - Non-D	Derivative S	Securi	ties Acqu	ired, Disposed of	, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Fransaction Date 2A. Deemed Execution Date, if any (Month/Day/Year)				quired of (D)	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	(Instr. 4)	
Common Stock	02/12/2014		A	5,000	A	\$0	50,013	D	
Common Stock	02/14/2014		M	3,444	A	\$ 9.97	53,457	D	
Common Stock	02/14/2014		M	22,500	A	\$ 9.97	75,957	D	
Common Stock	02/14/2014		S	22,500 (1)	D	\$ 79.54	53,457	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

### Edgar Filing: LIGAND PHARMACEUTICALS INC - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour Underlying Securit (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amo or Num of Sh
Employee Stock Option (right to buy)	\$ 9.97	02/14/2014		M		3,444	<u>(2)</u>	04/18/2021	Common Stock	3,4
Employee Stock Option (right to buy)	\$ 9.97	02/14/2014		M		22,500 (1)	<u>(2)</u>	04/18/2021	Common Stock	22,:
Employee Stock Option (right to buy)	\$ 74.42	02/12/2014		A	45,000		(3)	02/12/2024	Common Stock	45,0
Employee Stock Option (right to buy)	\$ 74.42	02/12/2014		A	10,000		<u>(4)</u>	02/12/2024	Common Stock	10,0
Employee Stock Option (right to buy)	\$ 74.42	02/12/2014		A	10,000		(4)	02/12/2024	Common Stock	10,0

# **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		

Reporting Owners 2

FOEHR MATTHEW W 11119 NORTH TORREY PINES ROAD, SUITE 200 LA JOLLA, CA 92037

EVP and COO

# **Signatures**

By: John P. Sharp For: Matthew W.

Foehr 02/14/2014

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 13, 2013, in accordance with Rule 10b5-1.
- (2) Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Optioned Shares per month thereafter.
- (3) Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/12/14.
- (4) The options vest upon satisfaction of certain performance criteria for the year ended December 31, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3